The BIOFIRE System is the new standard for syndromic infectious disease diagnostics. Simple, fast, and comprehensive, the BIOFIRE System delivers accurate results in about one hour.

The BioFire ME Panel identifies the most common viral, bacterial, and yeast pathogens that cause infections in the central nervous system, which in some cases can be life-threatening.

It takes just one syndromic test, one small sample of synovial fluid, and about an hour to get results on 39 clinically relevant targets. The BioFire JI Panel is intended to be used in CLIA …

The BioFire® FilmArray® Panels combine several possible pathogens into one rapid test, with results in about an hour. BioFire’s multiplex PCR technology is more sensitive than culture and …

BioFire offers a syndromic infectious disease testing approach that targets a broad menu of possible pathogens in one rapid test. Because of its ease of use, the BioFire System can be …

Excellence in customer support is a value deeply ingrained in the culture of BioFire. We want to provide our customers with the information needed to use our products with confidence and …

BioFire’s syndromic approach combines a broad grouping of probable pathogens into a single, rapid test. With the BioFire RP2.1plus Panel, all it takes is one test and just 45 minutes to …

The BioFire System performs syndromic PCR tests that detect infectious agents at the molecular level. With a revolutionary syndromic approach and the broadest target menu on the market, …

BioFire was acquired in 2014 by bioMérieux SA, a global leader in in vitro diagnostics for more than 55 years. For several years BioFire continued to maintain its brand identity and operations.

A BioFire syndromic test isolates, amplifies, and detects the DNA of microorganisms that cause overlapping signs and symptoms. The entire chemical process takes place inside a pouch, …